The FDA has approved EYLEA HD’s 8-milligram injection, or aflibercept, from Bayer and Regeneron Pharmaceuticals for treatment of patients with diabetic macular edema, wet age-related macular degeneration and diabetic retinopathy. Data from two Phase 3 trials showed that higher-dose Eylea posed no new safety issues and had similar efficacy as the lower-dose version when administered at longer intervals.
Full Story: Pharmaceutical Technology (8/21), Reuters (8/18)